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Background: Influenza viruses such as swine-origin influenza A(H1N1) virus (A(H1N1)pdm09) generate genetic
diversity due to the high error rate of their RNA polymerase, often resulting in mixed genotype populations (intra-
host variants) within a single infection. This variation helps influenza to rapidly respond to selection pressures, such
as those imposed by the immunological host response and antiviral therapy. We have applied deep sequencing to
characterize influenza intra-host variation in a transmission chain consisting of three cases due to oseltamivir-
sensitive viruses, and one derived oseltamivir-resistant case.
Methods: Following detection of the A(H1N1)pdm09 infections, we deep-sequenced the complete NA gene from
two of the oseltamivir-sensitive virus-infected cases, and all eight gene segments of the viruses causing the
remaining two cases.
Results: No evidence for the resistance-causing mutation (resulting in NA H275Y substitution) was observed in the
oseltamivir-sensitive cases. Furthermore, deep sequencing revealed a subpopulation of oseltamivir-sensitive viruses
in the case carrying resistant viruses. We detected higher levels of intra-host variation in the case carrying
oseltamivir-resistant viruses than in those infected with oseltamivir-sensitive viruses.
Conclusions: Oseltamivir-resistance was only detected after prophylaxis with oseltamivir, suggesting that the
mutation was selected for as a result of antiviral intervention. The persisting oseltamivir-sensitive virus population in
the case carrying resistant viruses suggests either that a small proportion survive the treatment, or that the
oseltamivir-sensitive virus rapidly re-establishes itself in the virus population after the bottleneck. Moreover, the
increased intra-host variation in the oseltamivir-resistant case is consistent with the hypothesis that the population
diversity of a RNA virus can increase rapidly following a population bottleneck.
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Influenza A (family Orthomyxoviridae) is a negative
sense, single-stranded RNA virus that infects a large va-
riety of hosts, including aquatic birds, humans and
swine. The influenza genome consists of eight segments,
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reproduction in any medium, provided the orencoding up to 13 proteins. Reassortment of the eight
segments between coinfecting strains results in genetic
diversity of influenza virus. Such multiple-reassortment
events occurring between numerous hosts were the
cause of at least two pandemics in the 20th century and
the 2009 pandemic due to the triple-reassortant swine-
origin A(H1N1)pdm09 virus [1].
In addition to reassortment, influenza viruses generate
genetic diversity due to the high error rate of their RNA
polymerase during transcription. This results in mixed
populations of virus genotypes within a single infectionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fitness [2]. Furthermore, the high mutation rate enables
the virus to rapidly adapt to selective pressures, whether
due to the host’s immune system or antiviral interven-
tion. Genetic change can result in a virus subtype acqui-
ring advantageous mutations such as those conferring
antiviral-resistance. As the progeny of the successfully
adapting viruses replace the other viruses in the popula-
tion, population bottlenecks occur [3]. These profoundly
affect the dynamics of virus evolution, and an improved
understanding of these intra-host processes may assist in
the development of more effective antiviral treatments.
Until recently, the genetic diversity of a virus popula-
tion could only be assessed by reverse-transcriptase PCR
(RT-PCR) [4], RT-PCR/electroscopy ionization mass
spectrometry (ESI-MS) [5], or by isolating and cloning
individual viruses and applying Sanger sequencing [6].
However, these approaches are time-consuming and la-
borious, hence only a few studies have analyzed influenza
populations in great detail [7-11]. Deep sequencing tech-
niques, including the Roche Genome Sequencer (GS)
FLX and Illumina Genome Analyzer (GA) platforms, can
detect low-frequency mutations and can provide consid-
erable information on intra-host virus populations and
the relative frequencies of virus variants. For instance,
Ramakrishnan et al. [8] performed the first full influenza
genome de novo Roche GS FLX sequencing for the pur-
pose of identifying mixed infections and intra-host vari-
ation. Other studies have applied deep sequencing to
patient samples from A(H1N1)pdm09-infected indivi-
duals to reveal intra-host diversity of the virus in relation
to the presence of oseltamivir-resistance conferring mu-
tations [7,9].
Here we present a case-study where the mode of A
(H1N1)pdm09 influenza transmission between four
infected individuals is known, with the emergence of
oseltamivir-resistant A(H1N1)pdm09 viruses in the last
of the cases (http://who.int/csr/disease/swineflu/notes/
h1n1_antiviral_resistance_20090708/en/index.html).
Using a novel real-time RT-PCR assay to initially detect
A(H1N1)pdm09, we subsequently applied deep sequen-
cing techniques to investigate the intra-host diversity in
the cases infected with oseltamivir-sensitive viruses com-
pared to the case carrying oseltamivir-resistant viruses.
The study
On 2 June 2009, Danish health authorities were notified
that a Danish family (a mother and her two children, 11
and 12 years old) had been in close contact with a con-
firmed case of A(H1N1)pdm09 influenza infection du-
ring a flight from the USA to the Netherlands. At the
time of notification, both children had influenza-like
symptoms (cases A and B). Upon returning to Denmark,
the family had close contact with seven people, one ofwhom developed influenza-like symptoms (sore throat,
aching muscles, fever) (case C). Throat swabs were taken
from all cases and contacts, and all were quarantined.
Clinical cases were treated with oseltamivir, while con-
tacts were given prophylactic doses of oseltamivir (see
Table 1 for dosages). Cases A, B and C subsequently
tested positive for oseltamivir-sensitive A(H1N1)pdm09
virus (described below), while the asymptomatic contacts
were all influenza negative. Four days after initiation of
oseltamivir prophylaxis, a second of the seven family con-
tacts (case D) developed influenza-like illness (fever, sore
throat, muscular pain) and tested positive for oseltamivir-
resistant A(H1N1)pdm09 by real-time RT-PCR. Case D,
who was in a close, personal relationship with case C, was
previously healthy without underlying chronic disease.
Contacts of case D were followed up but no cases due to
transmission of resistant virus were found.
Results
Real-time RT-PCR assays confirmed the presence of
A(H1N1)pdm09 in all four cases. Viruses recovered
from case C remained sensitive to oseltamivir, however,
A(H1N1)pdm09 viruses from case D exhibited a high
level of resistance (see Table 2 for neuraminidase inhibi-
tor test results). Viruses recovered from all cases
remained sensitive to zanamivir (Table 2).
Roche GS FLX sequencing of NA gene
We performed deep sequencing of the influenza NA
gene from all cases (cases A and B were uncultured,
whereas cases C and D were cell cultured), on the Roche
GS FLX, and full influenza genomes from cases C and
D, on the Illumina GAIIx, for the detection of intra-host
variants. Roche GS FLX sequencing yielded full coverage
of the NA genes from cases A, B, C and D with a re-
spective average depth of coverage of 198, 110, 127 and
85. The oseltamivir-resistance causing mutation site, en-
coding residue 275 (N1 numbering), was covered by se-
quences at a depth of 228, 93, 84 and 132 for cases A, B,
C and D, respectively. Cases A-C were homologous for
encoded histidine. This provides evidence against the
possibility that oseltamivir-resistant viruses were present
at detectable levels within the virus populations in these
3 individuals. However, 86% of the sequences in case D
(114/132) contained the resistance-conferring mutation
(see Table 3). Furthermore, cases A-C showed no sign of
intra-host variation at any locations throughout the NA
gene and case D contained no other sites with intra-host
variation other than the NA H275Y conferring mutation.
The Sanger sequencing of NA genes from cases C and D
corresponded to the Roche GS FLX generated se-
quences, and the NA master sequences from all cases
were identical with the exception of the NA H275Y con-
ferring mutation in case D.
Table 1 Specimen collection and oseltamivir treatment information
Patient Date of specimen collection A(H1N1)pdm+ or - Specimen type Dose (mg) Duration
A 2 June 2009 + Throat swab 60 twice daily 5 days
B 2 June 2009 + Throat swab 60 twice daily 5 days
C 2 June 2009 + Throat swab 75 twice daily 5 days
D 2 June 2009 - Throat swab 75 once daily 5 days
7 June 2009 + Throat swab None N/A
Footnotes: + indicates patient testing positive for A(H1N1)pdm09 based on RT-PCR, whereas – denotes negative result.
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Illumina GAIIx sequencing of cultured samples from
cases C and D yielded full genomes covered with a re-
spective average depth of 128 and 127. While 0/137 se-
quences contained the causative mutation on the NA
gene at nucleotide 823 in case C, 97% of the sequences
in case D (134/138) contained the resistance-conferring
mutation (see Table 4). The NA gene sequences gene-
rated by Sanger, Roche GS FLX and Illumina GAIIx se-
quencing for cases C and D all corresponded. Master
sequences can be found in NCBI for viruses recovered
from case C, A/Denmark/524/2009 (accession numbers
CY043339-46), and case D, A/Denmark/528/2009 (ac-
cession numbers CY043347-54).
Analysis for intra-host variants present in >2% of the
sequences across all 8 segments of the influenza genome
in cases C and D indicated variation at one, and seven
nucleotide positions respectively, including variation at
the oseltamivir-resistance conferring mutation in the NA
gene (Table 4). This variation consisted of five transi-
tions and three transversions and the eight single nu-
cleotide positions were in the PA, HA, PBI and NA
genes (Table 4). No intra-host variants were seen in the
NS, M, NP and PB2 genes. All variant positions were se-
quenced with high coverage (a minimum of 123) and
high quality (scoring 99 for genotype quality), indicating
that they were unlikely to be the result of sequencing
errors. Moreover, positions showing variation only
contained two possible bases corresponding to either
the dominant or the variant sequence, further reducingTable 2 Neuraminidase inhibition assay
Samples Oseltamivir
IC50 (nM)
Zanamivir
IC50 (nM)
Fold difference
compared to
sensitive control*
for Oseltamivir IC50
Sample C 4.5 2.5 3
Sample D 357 1.1 238
A/Norway/1758/07
(seasonal H1N1
sensitive control)
1.5 0.9 1
A/Norway/1735/07
(seasonal H1N1
resistant control)
494 0.8 329
Footnotes: *sensitive control refers to A/Norway/1758/07.the possibility of sequencing error. The log-scaled like-
lihood values supporting intra-host variation (AB) were
higher than the support for no variation (AA or BB in
Table 4) for all the variant sites, excluding variation at
nucleotide position 823 (conferring H275Y substitu-
tion) on the NA gene. However, given that the 275H
genotype was represented in only 3% of the sequences
from case D, the log-likelihood value was expected to
be low.
Seven of the eight nucleotide positions showing evi-
dence of intra-host variation caused non-synonymous
amino acid substitutions, with the synonymous substitu-
tion being associated with nucleotide 1800 in the PA gene
(Table 4). This high level of non-synonymous versus
synonymous substitutions is consistent with a previous
study [9], where Ghedin et al. deep sequenced intra-host
variants of an A(H1N1)pdm09 virus and determined that
there were 10 variant nucleotide positions causing 10
non-synonymous substitutions.
Five of the eight variant nucleotide positions, inclusive
of that encoding H275Y substitution, have been reported
previously (based on BLASTn and literature searches at
the time of manuscript preparation). A list of the top
BLASTn and literature results (limited to the top five)
can be found in Table 5. Other than the mutation en-
coding H275Y substitution, it is unknown whether the
other seven intra-host variant nucleotide positions have
any effect on the fitness of the virus.
Discussion
In this study, case C, who was treated with oseltamivir,
most likely infected case D, who was receiving prophy-
lactic doses of oseltamivir. Case C was sampled prior to
receiving oseltamivir, while case D was sampled five
days after oseltamivir prophylaxis commenced. It has
been suggested that resistant viruses carrying the NA
H275Y substitution suffer no fitness losses compared
with those with NA 275H wild-type in the absence of
drug intervention [12], and since samples were taken
from cases A-C prior to oseltamivir-treatment, it is not
possible to conclude whether resistance was acquired
during their treatment and resistant virus transmitted to
case D, or whether resistance emerged during prophy-
laxis in case D.
Table 3 Intra-host variant sites and frequencies in GS FLX sequences from the NA gene in patient D compared to GAIIx
sequences
nt
(Residue)
Dom
Base
Freq GS
FLX
Freq
GAIIx
Alt
Base
Freq GS
FLX
Freq
GAIIx
Total Coverage
GS FLX
Total Coverage
GAIIx
Variation (%)
GS FLX
Variation (%)
GAIIx
458
(S153N)
G 51 128 A 0 10 51 138 0 7
823
(H275Y)
T 114 134 C 18 4 132 138 86 97
Footnotes: ‘nt’ refers to nucleotide; ‘Dom’ refers to dominate base (G = S153, T = 275Y); ‘Freq’ refers to frequency; ‘Alt’ denotes alternative (A = 153N, C = H275).
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infecting case D (although it cannot be ruled out that
the infection originated from case A or B). Firstly, cases
A-C tested positive for A(H1N1)pdm09 influenza on
June 2nd and they were subsequently isolated. At this
time case D remained negative for A(H1N1)pdm09 in-
fluenza. Case C and D were in a close, personal relation-
ship and case D had only been in contact with case C
(rather than cases A or B) when case D developed symp-
toms. Secondly, looking to the consensus sequences
from patients C and D lends strong support to their epi-
demiological linkage. For all 8 segments it holds true
that the consensus sequences of the virus populations
are identical, with the exception of the H275Y conferring
mutation in the NA gene from case D. Additionally,
performing a BLASTn search against the GenBank
nucleotide database (online version as of 14/3 2012,
http://www.ncbi.nlm.nih.gov/blast) revealed that the HA,
NP and NS genes were uniquely identical, meaning that
they matched no other sequences in GenBank. The PB1
sequence matched only a single entry completely, and PB2
matched only 3 other entries (none of which share a pa-
tient origin with the PB1 hit), leaving only the PA and M
genes matching multiple, globally distributed, entries in the
database. For NA the sequences derived from patient C
also matched multiple hits whereas those encoding re-
sistance in patient D had a single perfect match.Table 4 Locations and details of genome nucleotide positions
Case Gene nt Dom base (freq) Alt base (freq) Total Cov Var
C PA 184 A(116) C(11) 127 9
D PA 1800 T(114) C(18) 131 14
D HA 844 A(103) G(33) 136 24
D PB1 437 C(106) T(22) 126 18
D PB1 796 C(103) A(20) 123 16
D PB1 1791 C(96) A(35) 131 27
D NA 458 G(128) A(10) 138 7
D NA 823 T(134) C(4) 138 97
Footnotes: ‘nt’ refers to nucleotide position. ‘Dom’ refers to dominant nucleotide. ‘
refers to frequency. ‘Var’ refers to level (%) of variant. ‘Log LH’ refers to log likelihoo
variation from the reference and AB represents some variation from the reference.
substitutions. The bold text highlights the variation associated with the NA H275Y,To date, few studies have reported on the intra-host
evolutionary dynamics of influenza viruses. One major
reason for this has been the limited capacity to detect low
frequency virus variants using conventional methods.
However, new deep sequencing technologies offer an
efficient and economic way to obtain a snapshot of the
entire virus population. During this study we demon-
strated the diversity between intra-host variants in
cases of oseltamivir–sensitive and oseltamavir–resistant
A(H1N1)pdm09 infections. While the master sequences
of these cases remained identical, but for the mutation
encoding the NA H275Y substitution, the subpopulations
of the virus quasispecies varied significantly. Interestingly,
case D contained a mixed population at nucleotide 823
on the NA gene, resulting in 3-14% (depending on the
sequencing platform used) of the viruses remaining sensi-
tive to oseltamivir. This result is similar to other reports
of mixed populations occurring in H275Y variant
A(H1N1)pdm09 viruses [9], and together they suggest
either that a small proportion of the sensitive viruses sur-
vive the treatment, or that the mutation conferring
oseltamivir sensitivity rapidly re-establishes itself in the
virus population after the bottleneck. These data also sug-
gest that the NA 275Y containing virus may be less fit
than the sensitive NA 275H virus, a hypothesis that is
supported by experiments in a ferret model [13], although
contradictory to the 275Y variant outgrowing the 275Hcontaining variation
% Log LH (AA) Log LH (AB) Log LH (BB) S or NS. Amino Acid
−48 −38 −501 NS I62L
−77 −39 −524 S S600
−142 −41 −478 NS I282V
−98 −38 −450 NS T146I
−86 −37 −430 NS L266I
−149 −39 −407 NS N597K
−48 −42 −552 NS S153N
−624 −41 −17 NS H275Y
Alt’ refers to alternative nucleotide. ‘Cov’ refers to sequence coverage. ‘Freq’
d, where AA represents no variation from the reference, BB represents 100%
‘S’ and ‘NS’ indicates synonymous and non-synonymous amino acid
oseltamivir-resistance conferring substitution.
Table 5 Top BLASTn and reference hits for intra-host variantsCase
Case Gene Variant nt Location Reference/Accession number Virus
C PA c CY018882 A/green wing teal/Ohio/175/1986(H2N1)
CY080052 A/mallard/Interior Alaska/8BM3519/2008(H12N5)
CY079192 A/mallard/Interior Alaska/8MP0792R1/2008(H12N5)
CY079120 A/northern pintail/Interior Alaska/8BM3582/2008(H3N8)
D PA 1800 CY097775.1 A/mallard/Mississippi/442/2010(H1N1)
CY062007.1 A/New York/7036/2009(H1N1)
CY060749.1 A/Ontario/9739/2009(H1N1)
JN584193.1 A/swine/Quebec/1257774/2010(H3N2)
CY073799.1 A/duck/Malaysia/2001(H9N2)
D HA 844 CY061741.1 A/swine/Hong Kong/2314/2009(H1N2)
Chakrabarti et al. (2009)29 Dk/India/TR-NIV4396/ 08(H5N1)
D PB1 437 - -
D PB1 796 - -
D PB1 1791 - -
D NA 458 HM598359.1 A/Thailand/CU-MV56/2010(H1N1)
Baz et al. (2010)28 A/Brisbane/59/2007-like(H1N1)
D NA 823 HM625654.1 A/Rome/PTV8/2009(H1N1)
HM598322.1 A/Thailand/CU-MV9/2010(H1N1)
CY092411.1 A/Sydney/DD3-48/2010(H1N1)
JF807497.1 A/Chennai/10/2009(H1N1)
CY091665.1 A/Singapore/GP4344/2010(H1N1)
Footnotes: BLASTn results for variant nucleotides were only included if they contained 100% identities. ‘nt’ refers to nucleotide.
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find the resistant 275Y virus to be attenuated in other
animal models [14]. In order for the oseltamivir-resistant
virus to be stable and more fit than the non-resistant
counterpart, other changes in the NA or HA genes may
have to be present as has been shown for the former
seasonal A(H1N1) virus during 2008 [15].
In addition to harboring a subpopulation of oseltamivir-
sensitive viruses, case D was noteworthy for the occur-
rence of seven additional intra-host variants. Only four of
the seven mutations have been reported in previous influ-
enza studies, three of which have been associated with A
(H1N1)pdm09 virus (including that conferring H275Y
substitution). Firstly, Baz et al. [16] reported that a NA
S153N substitution occurred concomitantly with the
H275Y substitution in an oseltamivir-resistant virus. Sec-
ondly, the mutation at residue 600 of the PA gene appears
in numerous consensus sequences submitted to the NCBI
database. Thirdly, the mutation conferring HA I282V sub-
stitution in A(H5N1) influenza virus, was reported by
Chakrabarti et al. [17], but it was not seen in combination
with NA H275Y substitution so is unlikely to be linked to
oseltamivir-resistance. The occurrence of these intra-host
variants in case D may be related to maintenance of virus
fitness. However, these mutations occur in non-conservedregions of the influenza A virus genome [18-21],
suggesting that they may have arisen as deleterious muta-
tions during a population expansion, with no direct correl-
ation to the NA H275Y conferring mutation.
Given one nucleotide change per 10,000 nucleotides
during replication and that most infections are caused
by 10–1,000 virions which likely possess varying num-
bers of nucleotide differences in their genomes, one can
expect that each influenza A virion is a possible intra-
host variant. However, we identify relatively few variant
sites, probably because currently available sequence
analysis software do not allow robust intra-host variant
analyses and manual curation is necessary. Hence, we
believe that with improved bioinformatic tools we would
detect more subpopulation variation in our sample set.
However, while our levels of intra-host variation seem
low, they are consistent with other second-generation
sequencing studies. Ghedin et al. [9] used a 10% cut-off
for including a variant. This conservatively high cut-off
ensured that variants were not determined by substitu-
tion errors (0.03% per nucleotide on the Roche GS FLX).
Using this cut-off, the authors detected only 10 sites
containing variation throughout the genome. Similarly
Ramakrishnan et al. [8] detected between 0 and 10 sites
with variation, depending on the sample.
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variation occurring in the virus populations in a transmis-
sion chain. There are, however, some limitations to the
methodology and processes that can influence the accurate
quantification of subpopulation variants: i) cell culturing
processes; ii) RT-PCR amplification; iii) emulsion PCR
(emPCR) and bridge PCR (in GS FLX and GAIIx sequen-
cing, respectively); and iv) the sequencing process.
Firstly, second-generation sequences for cases C and D
were determined from viral culture isolates rather than
from clinical specimens directly. It is possible that some
of the substitutions observed may have occurred during
passage of virus in cells, although reports of genetic vari-
ation occurring during MDCK cell passage are predom-
inantly linked to changes in the NA and HA genes [15].
MDCK cell cultures have been reported to select for
new variants, particularly for mutations leading to en-
hanced growth of virus in these cells [16]. However,
given that both cases C and D were cultured in much the
same manner, with only one passage more required for
case D, they allow direct comparison, with the H275Y
conferring mutation being the primary difference between
the samples. Additionally, reports of oseltamivir-resistant
viruses outgrowing sensitive viruses in MDCK and rhesus
monkey kidney cells might suggest that the 3-14% (GAIIx
and GS FLX results, respectively) of oseltamivir-sensitive
virus that we detected may be an under-estimate of
persisting oseltamivir-sensitive viruses in the case D pa-
tient [9,16]. Thus, a direct analysis of clinical specimens
for the polymorphisms at the sites listed in Table 3 would
be required to confirm these observations. However, due
to the low virus concentration in the case C and D clinical
samples, we were unable to convert the uncultured sam-
ples into libraries. Future generations of sequencing plat-
forms, such as the PacBio RS, requiring lower starting
amounts of template and the ability to sequence single in-
fluenza segments may resolve these issues.
Secondly, PCR-induced errors were minimized in the
preparation of the One-Step RT-PCRs and library amplifi-
cation steps by using Platinum and Phusion (respectively),
both high fidelity polymerases. Further, for the PCR repli-
cation step (5 separate reactions for the Illumina GAIIx
library template), a small number of amplification cycles
(18 cycles total) were used in the preparation of the ampli-
fied Illumina GAIIx library.
However, despite the aforementioned precautions,
evidence of amplification biases were still evident in the
variant sites detected in the NA gene of case D. The
H275Y conferring mutation was present in 86% and 97%
of sequences using the GS FLX and GAIIx platforms, re-
spectively. This difference is likely to represent biases in-
troduced during RT-PCR or emPCR/bridge PCR, rather
than during cell culturing given that these libraries were
constructed based on the same cell culture products.Repeating/duplicating the sequencing process could re-
solve this discrepancy. It should be noted that the GAIIx
library was built using 5 replicate RT-PCR reactions;
hence this could represent a more reliable variant fre-
quency measurement. The differences could also repre-
sent biases introduced due to the differences in GS FLX
and GAIIx library amplification and sequencing methods.
Moreover, we detected the NA S153N conferring muta-
tion in 7% of the sequences obtained on the GAIIx plat-
form but not those from the GS FLX platform. This could
be explained by: i) a nearly 3-fold decrease in coverage of
this site using the GS FLX platform (51-fold coverage com-
pared to 138-fold coverage on the GAIIx platform); ii) the
S153N conferring mutation arose as a sequencing error on
the GAIIx sequencer; or iii) preferential PCR or sequencing
bias in the GS FLX library for the dominant 153S encoding
sequences. Given that the S153N encoding variant was
present in 10/138 sequences, post-filtering, this anomaly is
most likely explained by hypotheses i) or iii).
Given that oseltamivir treatment would cause a virus
bottleneck, one might expect to see a reduction in the
genetic diversity of the virus population [22]. However,
this is not what was observed in case D, as was seen in an-
other A(H1N1)pdm09 study [9]. Specifically, Ghedin et al.
[9] compared virus sequences in specimens taken from an
individual prior to and after the emergence of oseltamivir-
resistance and detected no variation in the oseltamivir-
sensitive sample, compared to 10 nucleotide positions
showing variation in the resistant sample. There were no
common positions of nucleotide variation, excluding the
H275Y conferring mutation, between the resistant virus
specimens analyzed in the two studies.
How might one explain these observations? Previously
it was shown that RNA viruses can undergo rapid evolu-
tion following bottleneck events, leading to the accumu-
lation of neutral and deleterious mutations and, rarely,
the emergence of biologically fit variants [23,24]. There-
fore, in the present study, it would appear that the intro-
duction of oseltamivir either as treatment to case C or
as prophylaxis to case D created selective pressure that
caused the drug-resistant viruses to rapidly accumulate
in case D. However, as we had only one collection date
for each case in this study, we could not determine
whether or not the levels of virus variants remained
constant throughout the infections. For future studies of
intra-host variation it will be interesting to investigate
samples taken over time-series, both within single infec-
tions to monitor the variation within an individual, and
within longer transmission chains. The latter will enable
characterization of whether the unexpected diversity
post-bottleneck is maintained, or lost.
In conclusion, we used deep sequencing to characterize
the diversity of influenza viruses within a transmission
chain that involved the development of oseltamivir
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ence of low levels of oseltamivir-sensitive virus in the
case harboring oseltamivir-resistant viruses, suggesting
either survival through the treatment bottleneck, or
rapid re-evolution of the sensitivity-conferring mutation
post bottleneck. In addition, we paradoxically detected
higher levels of intra-host variation in the case harbor-
ing oseltamivir-resistant virus, compared to the case
carrying oseltamivir-sensitive virus. This contributes
evidence to support the hypothesis that post-bottleneck,
virus population expansions result in the generation of
greater levels of genetic diversity than are otherwise
found in the population.
Materials and methods
Ethics approval
Research carried out on humans was in compliance with
the Helsinki Declaration. Following the guidelines of the
National Board of Health (Denmark), informed consent
for use of the sequences in this paper was not required
from the sample sources, as the influenza viruses were an-
alyzed for clinical diagnosis under Danish Data Protection
Agency (Datatilsynet) permit number 2007-54-0364 pro-
vided to Dr Lars P. Nielsen, State Serums Institute. As re-
quired by this agreement, the identity of the patients
remains anonymous.
Consent
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images.
Virus isolation and extraction
Throat swabs collected from cases A-D and contacts
were suspended in 1 ml of virus transport medium,
200 μl of which was used for extraction of viral RNA by
a MagNA Pure LC Instrument applying the MagNa Pure
LC Total Nucleic Acid Isolation Kit (Roche diagnostics,
Basel, Switzerland).
RT-PCR diagnosis
Initial A(H1N1)pdm09 diagnosis was performed by
real-time RT-PCR. Extracted RNA (5 μl) was added to
20 μl of master mix consisting of 10 μM of each primer
and 2 μM of the Taqman probe together with reagents
from the OneStepW RT-PCR Kit (QIAGEN, Hilden,
Germany) according to the manufacturer’s instructions.
Primer sequences are available upon request. Target se-
quences were amplified on the MX3005 Thermocycler
system (Stratagene, CA, USA) with the following ther-
mal cycling parameters: 20 minutes at 50°C, 15 minutes
at 95°C followed by 45 cycles of 15 seconds at 95°C and
60 seconds at 55°C.Sanger sequencing
The NA genes from patient samples for cases C and D,
prior to cell culturing, were amplified by traditional one-
step RT-PCR and Sanger sequenced as previously de-
scribed [25]. We were unable to amplify all other gene
segments from cases C and D prior to cell culturing.
Inoculation and neuraminidase inhibition assay
Patient samples from cases C and D were inoculated onto
primary swine kidney cells (due to slow growth in MDCK
cells) and were further propagated on MDCK cells and in
10-days-old fertilized chicken eggs. Specifically, sample C
was passaged three times in swine kidney cells (titre 4 ×
105 TCID50/ml), while sample D was passage four times
in the same manner. The viruses were harvested and exam-
ined by neuraminidase inhibition assay to determine the NI
drug sensitivity phenotype, at the WHO Collaborating
Centre for Reference and Research on Influenza, London,
UK. Inhibition of neuraminidase activity was measured
using the fluorescent substrate, 2’-(4-methylumbelliferyl)-α-
D-N-acetylneuraminic acid (MUNANA; Sigma). Briefly,
20 μl of virus was incubated with 30 μl of 100 μM
MUNANA in 32.5 mM MES buffer pH 6.5 containing
4 mM CaCl2 for 1 hr at 37°C. The reaction was stopped by
addition of 150 μl 0.1 M glycine containing 25% ethanol
and 2% SuperQ pH 10.7 and fluorescence of the released
4-methylumbelliferone was measured at excitation and
emission wavelengths of 360 nm and 460 nm, respec-
tively. The activity of each virus sample was titrated, by
assaying serial twofold dilutions, and the amount of virus
adjusted to equivalent NA activities, which fell in the linear
portion of the activity curve. Each virus was preincubated
for 30 minutes at 37°C with oseltamivir or zanamivir at
final concentrations of 4 μM-15.3pM, in serial 4-fold dilu-
tions, NA activity measured and the drug concentration
that inhibited 50% of the neuraminidase activity (IC50) was
determined [26].
Deep sequencing
Roche Genome Sequencer FLX
The level of influenza RNA in the samples from cases A
and B was of insufficient quantity/quality to enable
complete influenza genome sequencing using universal in-
fluenza primers that co-amplify all 8 segments in a single
RT-PCR reaction [27]. Hence, Center for Disease Control
(CDC) primers were used to RT-PCR amplify the NA
genes from cases A, B (both patient samples), C and D
(both cultured samples) [28]. Although it would have been
preferable to obtain sequence from the uncultured patient
samples for cases C and D, to allow assessment of poten-
tial selection of sequence variants during the culture
process, we were unable to construct libraries on these
samples, hence the libraries were based on the cultured
samples. PCR products were converted into Roche GS
Fordyce et al. Virology Journal 2013, 10:116 Page 8 of 9
http://www.virologyj.com/content/10/1/116FLX libraries and were sequenced on 1/8th of a PicoTitre
Plate (PTP), using LR70 chemistry, following the manufac-
turer’s protocol (Roche, Basel, Switzerland).
Illumina GAIIx
An Illumina GAIIx was used for full influenza genome se-
quencing (all 8 gene segments) for cell-cultured virus from
cases C and D. In comparison to the Roche platform, the
Illumina GAIIx yields several orders of magnitude more
sequences in a single sequencing run, thereby allowing the
generation of deeper sequencing coverage of the influenza
genomes. Library building and sequencing of samples
were performed using a previously described method [29].
Briefly, full influenza genomes sampled from cases C and
D were converted into cDNA and amplified, in five separ-
ate SuperScript III One-Step RT-PCR reactions (with Plat-
inum Taq High Fidelity: Invitrogen, Carlsbad, CA)
reactions, using a previously published method [27]. The
temperature cycle parameters were 94°C for 30 sec, 45°C
for 30 sec, and 68°C for 3 min, followed by 31 cycles at
94°C for 30 sec, 57°C for 30 sec, and 68°C for 3 min. There
were two reasons for amplifying the samples in five separ-
ate RT-PCR reactions: firstly, to create a large volume of
sample that could then be concentrated; and secondly, to
reduce the effects of biases caused by RT-PCR amplifica-
tion. The five RT-PCR reactions were then pooled and
built into indexed Illumina GAIIx libraries using the
NEBNext Quick DNA Sample Prep Master Mix Set 2
(New England Biolabs, Ipswich, MA, USA) and sequenced
on 1 lane of an Illumina GAIIx following the manufac-
turer’s protocol (Illumina, San Diego, CA, USA) as part of
a larger pool of other libraries not relevant to this study.
Data analysis
Roche Genome Sequencer FLX
Sequence and quality files produced after sequencing were
manipulated using R scripts in order to obtain fastq files
suitable for subsequent processes. Roche GS FLX reads
were mapped to the Influenza A(H1N1)pdm09 prototype,
A/California/07/2009, NA gene (GI:229396468) using the
bwasw algorithm [30] included in the bwa v.0.5.9-r16
package: bwasw was preferred over the regular bwa due to
the length of sequence reads. Resulting bam files were fil-
tered for reads with two or more different mapping loca-
tions and chimeric reads (defined as having two or more
different mapping locations for different sections in the
read) for the following analyses, using Perl scripts. After
filtering, samtools v.0.1.14 [31] rmdup was used in order
to collapse PCR duplicates. PCR duplicates are defined as
reads with the same 5’ mapping position and orientation;
only the read with the highest mapping quality is kept.
Samtools ’mpileup’, with its default parameters, was used
on the sorted and collapsed alignments in order to pro-
duce a base pileup. Using the output from ’mpileup’,genotypes for each position were called using bcftools
which implements a Bayesian diploid SNP calling model,
based on base and mapping qualities. This model is useful
when attempting to characterize the intra-host diversity
due to its ‘calling of sites with variation’ capability.
Illumina GAIIx
Post Illumina GAIIx sequencing, data was sorted using
the method detailed in Kampmann et al. [29]. Briefly,
reads were aligned to the reference A/California/07/2009
sequences using bwa v.0.5.9-r16 [30]. The bam files were
manipulated using Perl scripts, along with samtools
v.0.1.14 [31], and GATK v.1.0.4641 M [32]. Coverage and
depth of coverage was calculated with GATK’s
DepthOfCoverage analysis. Variants were called using
GATK’s UnifiedGenotyper walker [33]. The resulting vcf
files were manually sorted to remove variants that oc-
curred only once (i.e. singletons) or at a frequency of less
than 2% of bases at the specific location.
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